Comment on

• Rituximab and lupus: good in real life, bad in controlled trials. Comment on the article by Lu et al.

  Ramos-Casals M, Díaz-Lagares C, Khamashta MA. Ramos-Casals M, et al. Arthritis Rheum. 2009 Sep 15;61(9):1281-2. doi: 10.1002/art.24726. Arthritis Rheum. 2009. PMID: 19714598 No abstract available.
• Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus.

  Nikpour M, Urowitz MB, Ibañez D, Gladman DD. Nikpour M, et al. Arthritis Rheum. 2009 Sep 15;61(9):1152-8. doi: 10.1002/art.24741. Arthritis Rheum. 2009. PMID: 19714602
• A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.

  Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, Petri MA, Ginzler EM, Chatham WW, McCune WJ, Fernandez V, Chevrier MR, Zhong ZJ, Freimuth WW. Wallace DJ, et al. Arthritis Rheum. 2009 Sep 15;61(9):1168-78. doi: 10.1002/art.24699. Arthritis Rheum. 2009. PMID: 19714604 Free PMC article. Clinical Trial.
• Disease activity and damage are not associated with increased levels of fatigue in systemic lupus erythematosus patients from a multiethnic cohort: LXVII.

  Burgos PI, Alarcón GS, McGwin G Jr, Crews KQ, Reveille JD, Vilá LM. Burgos PI, et al. Arthritis Rheum. 2009 Sep 15;61(9):1179-86. doi: 10.1002/art.24649. Arthritis Rheum. 2009. PMID: 19714612 Free PMC article.
• Novel evidence-based systemic lupus erythematosus responder index.

  Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, Chatham WW, Strand V, Weinstein A, Chevrier MR, Zhong ZJ, Freimuth WW. Furie RA, et al. Arthritis Rheum. 2009 Sep 15;61(9):1143-51. doi: 10.1002/art.24698. Arthritis Rheum. 2009. PMID: 19714615 Free PMC article.